The non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine ['Viramune'] is not associated with a higher risk of hepatotoxicity than other antiretroviral agents, according to results from Boehringer Ingelheim's Viramune® Hepatic Safety Project presented at the XIV International AIDS Conference [Barcelona, Spain; July 2002]. This analysis of data from controlled and uncontrolled clinical studies and observational cohorts showed that the majority of hepatic adverse events associated with nevirapine were asymptomatic and could be managed by treatment interruption.